Fda accepts eisai’s supplemental new drug application (snda) to update the labeling for anti-obesity agent belviq® (lorcaserin hcl) electricity outage san antonio

WOODCLIFF LAKE, N.J., Feb. 25, 2019 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New f gas regulations r22 Drug Application (sNDA) to potentially update the label for BELVIQ ® (lorcaserin HCl) CIV 10 mg twice-daily/BELVIQ XR (lorcaserin HCl) CIV once daily to include long-term